Clinical Trials Directory

Trials / Conditions / Botulism

Botulism

16 registered clinical trials studyying Botulism — 2 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingStudy of the Drug B11-FC (Botulism Treatment)
NCT06580236
Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian FederationPhase 1 / Phase 2
CompletedTolerability and Immunogenicity of a Single 40-ug Dose of rBV A/B for the Production of BabyBIG®
NCT06112834
California Department of Public HealthPhase 2
CompletedEffect of Amifampridine on Neuromuscular Transmission in Patients Treated With OnabotulinumtoxinA
NCT05769478
Wake Forest University Health SciencesPhase 1
UnknownUsing Shear Wave Ultrasound Elastography for Follow up After Anti-spastic Intervention Among Stroke Patients
NCT04550793
National Taiwan University Hospital—
CompletedTolerability and Immunogenicity of rBV A/B for the Production of BabyBIG®
NCT03676634
California Department of Public HealthPhase 2
CompletedA Study to Evaluate the Safety and Pharmacokinetics of NTM-1633 vs Placebo Administered Intravenously in Healt
NCT03603665
National Institute of Allergy and Infectious Diseases (NIAID)Phase 1
WithdrawnPhase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/B
NCT01940315
DynPort Vaccine Company LLC, A GDIT CompanyPhase 3
CompletedPhase I, Dose Escalation Study to Evaluate the Safety and Pharmacokinetics of NTM-1632
NCT02779140
National Institute of Allergy and Infectious Diseases (NIAID)Phase 1
CompletedBT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxi
NCT02055183
Emergent BioSolutions—
Enrolling By InvitationBT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients
NCT02051062
Emergent BioSolutionsPhase 4
CompletedSafety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B)
NCT01701999
California Department of Public HealthPhase 2
CompletedPilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism
NCT01441557
Centre Hospitalier Universitaire, AmiensPhase 2 / Phase 3
CompletedPhase 1 PK Study of XOMA 3AB
NCT01357213
National Institute of Allergy and Infectious Diseases (NIAID)Phase 1
CompletedBotulism Outbreak in Thailand (Episode II)
NCT00348426
Department of Medical Services Ministry of Public Health of Thailand—
CompletedTreatment of Survivors After Botulism Outbreak
NCT00314080
Department of Medical Services Ministry of Public Health of Thailand—
CompletedStudy of Human Botulism Immunoglobulin in Infants With Botulism
NCT00004401
California Department of Health ServicesN/A